Nebulized LAMA therapy for COPD

MAGNAIR® Nebulizer System with eFlow® technology features a vibrating, perforated membrane in a closed-system device

  • Delivers nebulized LAMA in 2 to 3 minutes, with proper setup and cleaning1,2
  • A closed-system device featuring eFlow technology3*
  • Requires a patient's natural tidal breathing, allowing for inhalation independent of inspiratory flow4
  • No hand/breath coordination, deep breaths, or breath-holding is required; multiple steps required for device setup and cleaning4

*The eFlow Closed System is part of PARI's electronic nebulizer platform. It features a vibrating, perforated membrane with laser-drilled holes that is designed to deliver consistently sized particles and to nebulize the solution for administration.3,5

 

Please see Important Safety Information below.

COPD, chronic obstructive pulmonary disease; LAMA, long-acting muscarinic antagonist.


 

References:

  1. LONHALA MAGNAIR [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; 2018.
  2. LONHALA MAGNAIR [instructions for use]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; 2017.
  3. Pham S, Ferguson GT, Kerwin E, et al. In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution [published online ahead of print November 10, 2017]. J Aerosol Med Pulm Drug Deliv. doi:10.1089/jamp.2017.1384.
  4. Dhand R, Dolovich M, Chipps B, et al. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD. 2012;9(1):58-72.
  5. PARI eFlow® Technology Device Comparison Chart. Foundation Care Pharmacy. https://www.foundcare.com/wp-content/uploads/2016/08/fnc_device_chart.pdf. Accessed January 25, 2018.

 

Important Safety Information & Indication 

Important Safety Information

LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with LONHALA MAGNAIR. If signs occur, discontinue LONHALA MAGNAIR immediately and institute alternative therapy.

LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥2% of patients taking LONHALA MAGNAIR, and occurring more frequently than in patients taking placebo, were dyspnea (4.9% vs 3.0%) and urinary tract infection (2.1% vs 1.4%).

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see full Prescribing Information and Patient Information for LONHALA MAGNAIR at www.sunovionprofile.com/lonhala-magnair.


Indication

LONHALA® MAGNAIR® (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.